China Government Releases New Regulation on Human Genetic Resource
On May 28, 2019, China’s State Council releases a new Regulation of Human Genetic Resources (the “Regulation”) which will become effective on July 1. For the life sciences industry and research organizations...
On May 28, 2019, China’s State Council releases a new Regulation of Human Genetic Resources (the “Regulation”) which will become effective on...
Read More
Will the United States Congress Clean-Up the Patent Eligibility Mess?
Steps are currently being taken by the United States congress to address the issue of patent eligible subject matter that has plagued the United States patent system in recent...
Steps are currently being taken by the United States congress to address the issue of patent eligible subject matter...
Read More
The “plausibility” threshold remains low in Australia
The requirement that a patent specification sufficiently enables the subject matter of the claims is particularly relevant to pharmaceutical inventions and can be a hurdle for innovators even if...
The requirement that a patent specification sufficiently enables the subject matter of the claims is particularly relevant to pharmaceutical...
Read More
Claim Drafting Tip: Written Description and Obviousness of Claims with Functional Features — Two Sides of the Same Coin
A recent precedential decision by the United States Federal Circuit (Nuvo Pharmaceuticals v DR. Reddy’s Laboratories (Fed Cir, No 17-2473, 15 May 2019) has provided valuable advice on the balance between...
A recent precedential decision by the United States Federal Circuit (Nuvo Pharmaceuticals v DR. Reddy’s Laboratories (Fed Cir, No 17-2473,...
Read More
Pharmaceutical patents: Fighting a $25 million claim for damages
A recent Full Federal Court decision in Australia provides a useful insight as to how a Court in Australia will calculate damages in proceedings concerning the infringement of a...
A recent Full Federal Court decision in Australia provides a useful insight as to how a Court in Australia...
Read More
New Zealand Update: ACTIPHEN Too Similar to ACTAZIN to Register
Anagenix opposed the Pharmazen’s application to register ACTIPHEN in connection with a range of medicinal food preparations (Class 5) and printed materials relating to those goods (Class 16).
Anagenix opposed the Pharmazen’s application to register ACTIPHEN in connection with a range of medicinal food preparations (Class 5)...
Read More
Case Note: H Lundbeck A/S & Anor v Sandoz Pty Ltd
A recent decision of the Federal Court of Australia has demonstrated that the launch of a pharmaceutical product by a generic company even after expiry of the standard term...
A recent decision of the Federal Court of Australia has demonstrated that the launch of a pharmaceutical product by...
Read More
Sigma Pharmaceuticals Case Clarifies Aspects of Compensable Loss
The recent decision in Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth FCA 1556 has clarified, among other things, a number of issues concerning compensation arising from the usual...
The recent decision in Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth FCA 1556 has clarified, among other things,...
Read More